Chapter 1. HIV THERAPEUTICS MARKET– Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. HIV THERAPEUTICS MARKET– Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-131 Impact Analysis

      2.3.1. Impact during 2023 – 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. HIV THERAPEUTICS MARKET– Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. HIV THERAPEUTICS MARKET- Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. HIV THERAPEUTICS MARKET- Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. HIV THERAPEUTICS MARKET– By Multi-class Combination Drugs

6.1. Triumeq

6.2. Symtuza

6.3. Stribild

6.4. Prezcobix/Prezista

6.5. Odefsey

6.6. Genvoya

6.7. Descovy

6.8. Complera

6.9. Atripla

6.10. Others

Chapter 7. HIV THERAPEUTICS MARKET– By Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

7.1. Truvada

7.2. Epzicom

7.3. Epivir

7.4. Emtriva

7.5. Biktarvy

7.6. Others

Chapter 8. HIV THERAPEUTICS MARKET– By Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

8.1. Edurant

8.2. Others

Chapter 9. HIV THERAPEUTICS MARKET– By Protease Inhibitors (PIs)

9.1. Viracept

9.2. Norvir

9.3. Lexiva

9.4. Kaletra

9.5. Aptivus

9.6. Others

Chapter 10. HIV THERAPEUTICS MARKET– By Entry Inhibitors

10.1. Selzentry

Chapter 11. HIV THERAPEUTICS MARKET– By HIV Integrase Strand Transfer Inhibitors

11.1. Isentress

11.2. Tivicay

Chapter 12. HIV THERAPEUTICS MARKET– By Region

12.1. North America

12.2. Europe

12.3. The Asia Pacific

12.4. Latin America

12.5. Middle-East and Africa

Chapter 13. HIV THERAPEUTICS MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Developments)

13.1. Company 1

13.2. Company 2

13.3. Company 3

13.4. Company 4

13.5. Company 5

13.6. Company 6

13.7. Company 7

13.8. Company 8

13.9. Company 9

13.10. Company 10

Download Sample